LENZ Therapeutics (LENZ) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 55.2% versus a loss of 92.7%. Over five years, LENZ leads with a -96.1% price change compared with -98.7% for OTLK. Outlook Therapeutics is the larger company by market cap ($138.9 million vs $113.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LENZ | OTLK |
|---|---|---|
| Share price | $3.61 | $0.5706 |
| Market cap | $113.27M | $138.91M |
| 1-day change | +2.13% | +1.17% |
| YTD return | -77.94% | -64.30% |
| 1-year return | -92.74% | -55.24% |
| 5-year return | -96.05% | -98.66% |
| EPS (TTM) | $-4.13 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.75 | $2.54 |
| 52-week low | $3.35 | $0.161 |
| Distance from 52-week high | -92.29% | -77.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +565.74% | +781.53% |
| Average volume | 833.64K | 13.33M |
| Shares outstanding | 31.42M | 243.45M |
| Employees | 152 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OTLK has outperformed LENZ by 37.5 percentage points over the past year.
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 152 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
LENZ vs OTLK FAQ
Which is bigger, LENZ Therapeutics or Outlook Therapeutics?
Outlook Therapeutics (OTLK) is larger, with a market capitalization of $138.91M compared with $113.27M for LENZ Therapeutics (LENZ).
Which stock has performed better over the past year, LENZ or OTLK?
OTLK returned -55.24% over the past 12 months, compared with -92.74% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are LENZ Therapeutics and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.